Supernus Pharmaceuticals Inc
SWB:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
Novacyt SA
F:NYZ
|
FR |
|
G
|
Grammer AG
XBER:GMM
|
DE |
|
Huatai Securities Co Ltd
LSE:HTSC
|
CN |
|
S
|
Sany Heavy Equipment International Holdings Company Ltd
F:YXS
|
CN |
|
F
|
First Industrial Realty Trust Inc
F:F5W
|
US |
|
R
|
Realty Income Corp
XMUN:RY6
|
US |
|
G
|
Gen Digital Inc
DUS:SYM
|
US |
|
I
|
IDEXX Laboratories Inc
F:IX1
|
US |
|
Perrigo Company PLC
F:PIG
|
IE |
|
Woodside Energy Group Ltd
ASX:WDS
|
AU |
|
V
|
Verizon Communications Inc
XMUN:BAC
|
US |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 55.57 EUR with a low forecast of 48.16 EUR and a high forecast of 60.09 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
55.57
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 55.57 EUR with a low forecast of 48.16 EUR and a high forecast of 60.09 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 3 years is 18%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 3 years is 16%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
205%
The compound annual growth rate for Operating Income over the next 3 years is 205%.
